CD97, an adhesion-linked G-protein coupled receptor (GPCR), is induced in multiple epithelial cancer lineages. We address here the signaling properties and the functional significance of CD97 expression in prostate cancer. Our findings show that CD97 signals through GĮ12/13 to increase RHO-GTP levels. CD97 functioned to mediate invasion in prostate cancer cells, at least in part by associating with lysophosphatidic acid receptor 1, (LPAR1), leading to enhanced LPA-dependent RHO and ERK activation. Consistent with its role in invasion, depletion of CD97 in PC3 cells resulted in decreased bone metastasis without effecting subcutaneous tumor growth.
Introduction
Expression of the G-protein coupled receptor (GPCR) CD97 is induced in a variety of epithelial cancers. CD97 is normally expressed on cells of hematopoetic origin and smooth muscle but is expressed at very low levels or is absent in normal epithelial cells (1, 2) . Carcinomas derived from various epithelial tissues consistently demonstrate increased CD97 expression compared to normal adjacent tissue and in some cases, the level of CD97 expression positively correlates to tumor grade and poor prognosis. CD97 induction has been described in thyroid (3), colorectal (4), gastric, pancreatic, esophageal (3), oral squamous cell (5) , and prostate carcinomas (6) . It has been unclear as to whether CD97 is a marker of epithelial transformation, or alternatively, might play a functional role. Of interest is the description of CD97 at the invasion front of carcinomas, hinting at a potential function in progressing cells (3) . However, the existence of CD97-dependent signaling associated with tumors has not been established.
Here we have investigated whether CD97 plays a functional signaling role in prostate cancer.
CD97 is a member of the adhesion-linked GPCRs, a family of membrane-bound proteins characterized by a large extracellular subunit containing one to a few adhesion motifs noncovalently associated with a conserved GPCR seven-transmembrane domain (TM7) (7) . Most adhesion-linked GPCRs are translated as a single polypeptide that is proteolytically processed intracellularly to produce the two associated subunits. CD97
belongs to a subclass of adhesion GPCRs that contain variable numbers of EGF-like repeats in the extracellular adhesion domain (1) . Although the adhesion GPCR family members are thought to have the dual potential of cellular adhesion and signaling, a mechanistic understanding of adhesion coupled signaling has not been established (2) .
Heterotrimeric Gα 12/13 dependent signaling has been shown for one family member, GPR56, but signaling has not as yet been linked to binding of the known ligand, Transglutaminase 2 (8, 9) . In addition, two receptors, BAI1 and LTR, have known ligand-dependent functions which require the transmembrane regions, but it has not been established functionally whether heterotrimeric G-protein signaling is needed (10, 11) . Specific CD97 isoforms have been shown to interact with integrins α5β1 and αvβ3 (12) , ѽ the cell surface complement regulatory protein CD55 (13) , and the extracellular matrix component chondroitin sulfate (14) , although ligand-dependent signaling has not been shown.
In the present study we demonstrate that CD97 complexes in cis with and positively regulates LPAR1, a cognate receptor for lysophosphatidic acid (LPA), resulting in increased LPA-dependent RHO signaling. LPA is a bioactive phospholipid that acts as a high affinity ligand for LPARs to mediate various cellular functions that contribute to transformation including proliferation, survival, cytoskeletal restructuring, and production of secreted factors such as cytokines and metalloproteases (15, 16) .
Bioactive LPA is produced in the extracellular matrix when complex lysopholipids, predominantly lysophosphatidylcholine, are hydrolyzed by the secreted enzyme, autotoxin (ATX). Elevated LPA production (17) and increased expression of cell surface LPARs (18, 19) modifies LPA-initiated signaling, a finding that lends mechanistic understanding to the potential importance of CD97 induction in carcinomas.
Materials and Methods
The following technical information is provided in the Supplementary Data: "Antibodies and Reagents," " Expression Constructs," "Immunohistochemistry,"
"SRE-luciferase reporter assay," "Facs analysis and cell sorting," "CD97 silencing," and "In situ proximity ligation assay."
Cell-culture
DU145, PC3, and LNCaP prostate cancer cells were obtained from ATCC. PC3 cells permanently expressing a luciferase reporter were generated and cultured as reported (21) . All culture media and reagents were from Invitrogen.
Immunofluorescence and confocal microscopy
Staining and image acquisition by confocal microscopy were carried out as previously described (22) . Mouse monoclonal antibodies directed against HA and vinculin were used at a 1:1000 dilution.
Preparation of cell blocks
Prostate cells were made into cell blocks using the fibrin clot method as described (23) . Blocks were fixed in 10% formalin and paraffin embedded. Sections were prepared and stained using the immunohistochemistry procedure.
Immunoprecipitation and western blot analysis
Relative levels of myc-tagged CD97-3EGF and myc-tagged CD97β were determined by transfecting COS 7 cells with varying amounts of DNA using Lipofectamine Plus. Lysates were prepared and immunopreciptations and western blots were performed as described (24) . Coimmunoprecipitation assays were performed as described (25) . The amount of GTP bound RHOA was determined using the RHO activation assay kit (Upstate Cell Signaling Solutions).
In vitro invasion and migration
Invasion chambers were prepared as described previously (12) except that growth factor reduced matrigel (BD Bioscience) was used. DU145 cell invasion was performed as described (25) . For Rho inhibition cells were resuspended in medium containing CT04 (2μg/ml). PC3 and LNCaP transmigration was set up as described above except that BSA was not added to the serum free media and cells were allowed to migrate for 24 hours.
Migration was carried out the same way as in vitro invasion except that the membrane was coated with gelatin instead of matrigel.
PC3 metastasis assay
Experimental metastasis assays and bioluminescent imaging were done as described previously (21) .
Results

CD97 expression is induced in prostate adenocarcinomas and is expressed in some prostate cancer cell lines.
Immunohistochemical analysis of a prostate cancer tissue array indicated that CD97 was expressed in the membrane and cytoplasm of adenocarcinoma cells while it was undetectable in normal adjacent prostate epithelium (Fig. 1A) . For the majority of prostate cancer samples, the CD97 staining intensity was relatively uniform, while the FACS analysis of various prostate cell lines stained for CD97 revealed differential cell surface expression. Non-transformed, primary prostate cells (RWpE-1) were negative, while we observed both positive (PC3 and DU145) and negative (22RV1 and LNCaP) prostate adenocarcinoma-derived cells lines (Fig. 1B) . Western blot analysis produced similar results except that 22RV1 cells appeared to express very low levels of CD97 not detected by the FACS analysis (Fig. 1C) . The expression patterns of CD97 in the prostate cancer tissue array and in different prostate cell lines confirm an earlier report that CD97 is induced in prostate adenocarcinomas (6) .
Ectopic overexpression of CD97 stimulates Gα 12/13 dependent RHOA activation
Although CD97-mediated signaling has not yet been elucidated, the conserved GPCR transmembrane structure of CD97 suggests that its function is G-protein coupled.
There are a number of examples of highly-expressed GPCRs that induce signal activation in a ligand-independent manner (26). Here we combined ectopic CD97 overexpression with assays for various signal transduction pathways. We observed CD97-dependent induction of activity for the transcriptional reporter SRE-luciferase, an indicator of RHOA activity that is commonly used to assay Gα 12/13 activation (27) . Transient transfection of COS 7 cells with constitutively activated forms of RHOA and Gα 12 but not Gα q ( Fig. 2A) resulted in significantly elevated levels of normalized SRE-dependent luciferase activity, verifying the expected specificity of the assay.
A variety of CD97 receptor configurations were assayed including 1) full-length CD97 containing either three or five EGF-like repeats, 2) the GPCR portion of CD97 (denoted CD97β), and 3) a GPCR-deficient control (denoted CD97-TM1) which consists of the extracellular region and only the first transmembrane segment. Full-length CD97 stimulated about a four-fold increase in activity, while GPCR-deficient CD97 was inactive. It is of interest that the CD97 GPCR β subunit alone stimulated a 50-fold increase in SRE-luciferase activity, suggesting higher constitutive activity of the β subunit in the absence of the interacting extracellular domain (note the scale difference between the left and right panels of Fig. 2A ). To normalize SRE activity relative to the level of CD97 GPCR subunit expression, the amount of DNA encoding C-terminal epitope-tagged full-length or β only CD97, was titrated in transfections and the transfected cells were subsequently assayed for protein amount and luciferase activity. A comparison of similar levels of GPCR subunit expression (Fig. 2C) showed a five-fold increase for full-length CD97 and a 19-fold increase for the β construct in SRE-luciferase activity.
To determine whether CD97-stimulated SRE activity was dependent upon specific inhibition but did not decrease downstream signals such as constitutively active RHOA-dependent SRE activity. As shown in Figure 2A , RGS-p115 almost entirely inhibited full-length CD97-dependent SRE activity and inhibited about 80% of CD97β-dependent SRE activity. To investigate whether SRE activation by CD97 was RHOdependent, an expression construct for C3 exoenzyme, which specifically inhibits RHO as a result of ADP-ribosylation, was co-transfected with CD97 or control plasmids into COS 7 cells. The C3 exoenzyme blocked RHOA-dependent SRE activity, as expected.
In addition, Gα 12 -dependent SRE activity was substantially inhibited, indicating that the Gα 12 -stimulated activity was predominantly through RHO activation. All CD97-stimulated SRE-luciferase activity was inhibited by C3 exoenzyme demonstrating strong RHO-dependence ( showing that the majority of CD97-dependent migration was RHOA-dependent ( Fig.   3B ). We also investigated the impact of CD97 depletion on potential Gα 12/13 downstream mediators that are known to play a role in cellular migration and invasion. Figure 3C shows that CD97 depletion led to decreased phospho-ERK and phospho-AKT levels that were restored to parental DU145 levels by CD97 re-expression. We did not observe an effect on cell growth in vitro. LPA initiated signaling was assayed in parental and CD97-depleted cells, and we observed reductions in RHOA-GTP, phospho-ERK and phospho-AKT levels, similar to the pattern previously seen in CD97-depleted cells grown in serum-containing medium.
By contrast, for HGF-stimulated cells, CD97 depletion reduced the relatively weak RHO-GTP signal but had minimal effects upon phospho-ERK and phospho-AKT levels ( 
CD97 depletion in PC3 cells reduces experimental bone metastasis but not subcutaneous growth.
To address the role of CD97 in tumorigenesis and experimental metastasis, we used the PC3 prostate cancer cell line transfected with a luciferase expression construct (PC3-luc). Figure 4A shows that shRNA-mediated knockdown of CD97 in PC3 cells resulted in suppression of GTP-bound RHO and ERK activity, consistent with our findings for DU145 cells. However, phosphorylation of AKT was not affected by CD97 expression in PC3 cells. Similarly to DU145, invasion of PC3 cells to LPA was significantly reduced following CD97 knockdown or addition of CT04, indicating that the invasion was predominantly CD97 and RHO-dependent (Fig.4B ). There was no apparent effect of CD97 depletion upon cell growth in vitro. 
same in the experimental and control groups. Figure 4C shows representative bioluminescence and histological images for each of the metastatic sites. Table 2 (Fig 4C) .
Taken together, this data suggests that CD97 expression has a significant effect upon the ability of PC3 cells to initiate metastasis, consistent with effects upon migration, invasion, and/or colonization.
CD97 heterodimerizes with LPA receptor 1 resulting in enhanced invasion
Mechanistic studies were pursued to investigate the significant effect of CD97 depletion on LPA-initiated invasion and signaling. There is increasing evidence that Gprotein coupled receptors can exist as selective heterodimers with specific ligand responses. We hypothesized that CD97 regulates RHO activity in prostate cancer cells at least in part by interacting with LPA receptors. LPAR1, which is expressed in PC3 and DU145 but not LNCaP, has been linked to LPA-initiated migration (18, 19 to assay an LPAR1-CD97 interaction are limited by a lack of sufficiently sensitive precipitating antibodies for endogenous levels of LPAR1 protein. Therefore, we generated constructs coding for tagged proteins to first analyze the CD97-LPAR1 interaction (Fig.5A) . CHO cells were transiently transfected with HA-tagged LPAR1 and myc-tagged CD97-3EGF, and antibodies directed to either myc or to HA coimmunoprecipitated the other GPCR, indicating an interaction between LPAR1 and CD97 ( Figure 5B ).
We used the same strategy to look at LPAR1-CD97 heterodimer formation in LNCaP prostate cancer cells that are known to lack LPAR1 (18) and CD97 ( Fig. 1B and   C ). LPAR1-HA, CXCR4-HA, and CD97-myc were permanently transfected into LNCaP cells in the appropriate combinations and assayed for cell surface expression (Supplementary Figure 3) . In coimmunoprecipitation studies, an LPAR1-CD97 interaction was readily detectable (Fig. 5C ) while CXCR4 coimmunoprecipitated far less CD97. To independently confirm LPAR1-CD97 interactions, we used the in situ proximity ligation assay (DuoLink) to detect heterodimer formation in permanentlytransfected LNCaP cells (34) . The red dots on the cell membranes shown in Figure 5D indicate the localization of interacting proteins confirming that interacting LPAR1 and CD97 are in the same cell. Quantifications of the average signals or heterodimers for each cell line (Fig. 5E ) demonstrated significant interaction between LPAR1 and CD97, whereas the degree of interaction between CXCR4 and CD97 was substantially lower. To verify that the introduced HA-tagged LPAR1 would interact with endogenous CD97, we the permanently transduced parental cells and on 65% of the CD97-depleted cells. Using the DuoLink assay we observed that endogenous CD97 heterodimerizes with introduced LPAR1 in DU145 cells and that the LPAR1-CD97 interaction is lost upon CD97 depletion (Fig. 5F ).
To determine if formation of CD97-LPAR1 heterodimers enhances LPAstimulated invasion in LNCaP cells, we subjected cells expressing each receptor alone or both LPAR1 and CD97 or CXCR4 and CD97 to invasion through a thin layer of matrigel.
The chemoattractants LPA and SDF-1 were used for LPAR1 and CXCR4, respectively. Figure 5G shows that LPAR1 expression was sufficient to allow LPA-initiated migration, and that coexpression of CD97 and LPAR1 in LNCaP cells resulted in enhanced RHOdependent invasion relative to LPAR1 alone. By contrast to LPA-stimulated migration, SDF-1 stimulated a weak migratory response in CXCR4 expressing cells that was not improved by CD97 coexpression (Fig. 5H) . We conclude from our findings that CD97 and LPAR1 form heterodimers resulting in enhanced cell invasion in response to LPA stimulation. ( Fig 1A) . In addition, about 80% of adenocarcinomas demonstrated staining for LPAR1 with a shift toward more intense staining relative to normal prostate (Supplementary Figure 4 and Table 1 ). Interestingly, statistical analysis (Fisher's Exact Test) revealed a significant association between the presence of CD97 and LPAR1 expression (P<0.01) in adenocarcinomas.
CD97 expression positively correlates with LPAR1 in a prostate tissue array
Discussion
The abnormal expression of CD97 in carcinomas has been described for various tissue origins. Here we show CD97 expression in clinical samples of prostate adenocarcinoma occurred at a high frequency (60%) across Gleason grades, while there was no detectable expression in normal prostate. An earlier study using a different antibody reported enhanced CD97 expression in prostatic intraepithelial neoplasia and localized prostate cancer relative to low levels of expression in normals (6) . Taken together, these data suggest that CD97 induction occurs early in prostate cancer progression. The potential significance of induced CD97 expression in prostate adenocarcinoma was investigated by analyzing the signaling properties of CD97 and the functional contribution of CD97 to prostate cancer invasion and experimental metastasis.
We show here that ectopic CD97 induces Gα 12/13 -dependent RHOA activation, demonstrating intact heterotrimeric G-protein dependent signaling for the CD97βҏ subunit. Depletion of endogenous CD97 in DU145 and PC3 cell lines inhibited LPAstimulated RHOA and ERK pathway activation. Consistent with decreased signaling, CD97 depletion inhibited LPA-stimulated invasion. By contrast, CD97 depletion had a significantly smaller effect upon HGF-initiated signaling and invasion. Thus, CD97 
action appears to be linked to LPA-initiated functions. A complementary approach using reconstitution was performed in LNCaP cells, which do not normally express CD97 or LPAR1. In this case, CD97 increased LPA-initiated LPAR1-dependent invasion. These in vitro data were extended in vivo for PC3 cells, to demonstrate that CD97 depletion reduced metastatic colonization to the bone by more than half, suggesting an effect upon early tissue invasion and/or the establishment of micrometastases. Interestingly, in breast cancer, the LPA/LPAR pathway has been associated with bone metastases. In a xenograft model, LPAR signaling promoted both the establishment and subsequent expansion of osteolytic bone metastases (35).
We investigated the possibility that CD97-LPAR heterodimerization could mechanistically explain the positive effect of CD97 expression on LPA-initiated signaling. Using both ectopic expression and shRNA-mediated depletion, it was possible to demonstrate physical complex formation between epitope-tagged LPAR1 and either tagged or endogenously-expressed CD97. It is possible that there exist additional interactions between CD97 and other GPCRs. However, one measure of specificity for the LPAR-CD97 interaction was indicated by the lack of physical and functional interaction between CD97 and CXCR4, a GPCR that has been suggested to play a role in prostate cancer invasion (36) . Immunohistological analysis of clinical prostate cancer samples revealed that LPAR1 is expressed in normal prostate and in about 80% of adenocarcinomas, with relatively increased levels compared to normal epithelium. There was a significant association of CD97 and LPAR1 expression in adenocarcinomas, confirming the potential for these receptors to synergize in prostate cancers. The role of the LPA-LPAR axis in tumorigenesis and metastasis has been well established (15 CAN-11-2381 Thus, the data presented here provide a mechanistic rationale for induced CD97 expression in prostate carcinomas. Further analysis to test for the generality of the LPAR-CD97 association across tissue types will be of interest.
We describe the positive regulation by CD97 of ligand-dependent LPAR1 signaling. We have found no indication for ligand-dependent CD97 function in the context investigated here. For serum stimulated invasion of prostate cancer cells, there were no effects of blocking antibodies directed to previously identified CD97 cell surface ligands including integrins α5β1 and αvβ3 as well as CD55. Of course, we cannot exclude the possibility that other unidentified CD97 ligands are required. Thus, preliminarily, CD97 and LPAR1 heterodimerization appears to exemplify ligand independent (CD97) regulation of ligand-dependent (LPAR) GPCR function. Several mechanisms have been identified for other heterodimerized GPCR's that account for positive regulation by a ligand-independent partner (37). Since both CD97 and LPAR1 couple to Gα 12/13 , one potential mechanism of synergy is the reinforcement or amplification of RHO-dependent signaling (15) .
The data presented here have practical implications. LPA receptors are considered promising therapeutic targets for cancer treatment, and drugs that inhibit the LPA-LPAR axis are being developed (38) . Increased expression of CD97 has been observed in a number of carcinomas and induced expression of the closely-related receptor, EMR2, has been described in breast cancer (39) 
